|Bid||4.48 x 168000|
|Ask||4.56 x 164000|
|Day's Range||4.56 - 4.58|
|52 Week Range||3.39 - 8.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors are always looking for growth in small-cap stocks like BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), with a market cap of USD $460.19M. However, an important fact which most ignore is: howRead More...
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
The Durham, North Carolina-based company said it had a loss of 21 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.
The Durham, North Carolina-based company said it had a loss of 19 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
BioCryst Pharmaceuticals, Inc. (BCRX) has been on the move lately as the stock has risen by 46.8% in the past four weeks, and it is currently trading well above its 20-Day SMA